SM
MCRB icon

SG3 Management’s Seres Therapeutics MCRB Stock Holding History

SG3 Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,200
Closed -$200K – 1217
2021
Q4 		$200K Sell
1,200
-1,435
-54% -$228K ﹤0.01% 807
2021
Q3 		$367K Buy
2,635
+1,185
+82% +$232K 0.01% 663
2021
Q2 		$692K Sell
1,450
-50
-3% -$21.1K 0.02% 577
2021
Q1 		$618K Buy
+1,500
New +$691K 0.02% 716

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SG3 Management's MCRB Position: Q2 2021 in Review

SG3 Management sold out of Seres Therapeutics (MCRB) in Q2 2021, closing a stake of 1,000 shares — an estimated $422K sold.

SG3 Management first reported a position in MCRB in Q1 2021 and held it in 1 quarter. The position peaked at $412K in Q1 2021. 146 funds tracked by Wall St. Rank hold MCRB as of Q2 2021.

  • SG3 Management reported no remaining Seres Therapeutics position as of Q2 2021 after selling out during the quarter.
  • SG3 Management sold 1,000 Seres Therapeutics shares in Q2 2021, an estimated $422K.
  • SG3 Management first reported a position in Seres Therapeutics in Q1 2021 and held it in 1 quarter.
  • SG3 Management's Seres Therapeutics position peaked at $412K in Q1 2021.
  • 146 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.